

# Alexander J Thompson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11138310/publications.pdf>

Version: 2024-02-01

66  
papers

8,788  
citations

159585

30  
h-index

114465

63  
g-index

68  
all docs

68  
docs citations

68  
times ranked

8413  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. <i>Nature</i> , 2009, 461, 399-401.	27.8	3,394
2	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
3	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 139, 120-129.e18.	1.3	633
4	ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. <i>Nature</i> , 2010, 464, 405-408.	27.8	430
5	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1888-1896.	7.3	332
6	An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. <i>Gastroenterology</i> , 2010, 139, 821-827.e1.	1.3	285
7	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. <i>Gastroenterology</i> , 2010, 139, 1181-1189.e2.	1.3	171
8	Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1736.	7.4	114
9	Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function. <i>Gastroenterology</i> , 2011, 140, 1314-1321.	1.3	111
10	Quantitation of pretreatment serum interferon- $\lambda$ 3-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. <i>Hepatology</i> , 2011, 53, 14-22.	7.3	94
11	Eradication of hepatitis C infection: The importance of targeting people who inject drugs. <i>Hepatology</i> , 2014, 59, 366-369.	7.3	78
12	Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. <i>Gut</i> , 2012, 61, 128-134.	12.1	76
13	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.	7.3	67
14	Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1-9.	2.8	67
15	Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 890-899.	8.1	64
16	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. <i>Hepatology</i> , 2012, 56, 444-454.	7.3	61
17	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1900-1906.	5.8	61
18	Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. <i>Hepatology</i> , 2011, 54, 772-780.	7.3	56

#	ARTICLE	IF	CITATIONS
19	Interferon-free combination therapies for the treatment of hepatitis C: current insights. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 51.	2.5	52
20	Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. <i>Hepatology</i> , 2016, 63, 1205-1212.	7.3	51
21	The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. <i>PLoS ONE</i> , 2015, 10, e0142770.	2.5	49
22	Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 872-882.	2.8	47
23	Australia needs to increase testing to achieve hepatitis C elimination. <i>Medical Journal of Australia</i> , 2020, 212, 365-370.	1.7	43
24	Current and emerging antiviral treatments for hepatitis C infection. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 931-943.	2.4	42
25	IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 861-866.	2.8	41
26	Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2012, 56, 313-319.	3.7	39
27	Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. <i>International Journal of Drug Policy</i> , 2019, 72, 91-98.	3.3	39
28	Resistance to anti-HCV protease inhibitors. <i>Current Opinion in Virology</i> , 2011, 1, 599-606.	5.4	36
29	High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. <i>Hepatology</i> , 2011, 53, 1809-1818.	7.3	36
30	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. <i>Medical Journal of Australia</i> , 2021, 214, 475-483.	1.7	36
31	Treatment access is only the first step to hepatitis C elimination: experience of universal antiviral treatment access in Australia. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1223-1229.	3.7	34
32	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	4.0	31
33	Point-of-Care Tests for Hepatitis B: An Overview. <i>Cells</i> , 2020, 9, 2233.	4.1	30
34	Host genomics and HCV treatment response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 212-222.	2.8	29
35	Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. <i>Hepatology</i> , 2010, 52, 2243-2244.	7.3	28
36	Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?. <i>Hepatology</i> , 2012, 56, 373-381.	7.3	28

#	ARTICLE	IF	CITATIONS
37	Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs. <i>Journal of Viral Hepatitis</i> , 2019, 26, 919-922.	2.0	27
38	The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2213-2221.	2.3	25
39	<i>ITPA</i> genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160.	7.3	25
40	Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. <i>Journal of Hepatology</i> , 2012, 56, 557-563.	3.7	24
41	The role of viral and host genetics in natural history and treatment of chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 413-427.	2.4	24
42	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 805-813.	8.1	22
43	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	5.8	21
44	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. <i>BMC Medicine</i> , 2019, 17, 175.	5.5	17
45	Delivery of care for functional gastrointestinal disorders: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 204-210.	2.8	17
46	A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. <i>International Journal of Drug Policy</i> , 2020, 76, 102633.	3.3	17
47	Genetic Factors and Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1335-1339.	1.3	16
48	Outcome of hospital outpatient treatment of functional gastrointestinal disorders. <i>Internal Medicine Journal</i> , 2019, 49, 225-231.	0.8	16
49	Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review. <i>Seminars in Liver Disease</i> , 2019, 39, 341-353.	3.6	16
50	Redefining Baseline Demographics: The Role of Genetic Testing in Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2011, 15, 497-513.	2.1	14
51	Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2102-2111.e9.	4.4	14
52	The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services. <i>PLoS ONE</i> , 2020, 15, e0235445.	2.5	12
53	The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 375-384.	2.0	11
54	Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 739-747.	4.0	10

#	ARTICLE	IF	CITATIONS
55	Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 20, 100359.	2.9	10
56	The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. <i>Viruses</i> , 2022, 14, 497.	3.3	7
57	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018, 13, e0199198.	2.5	6
58	IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. <i>Biomarkers in Medicine</i> , 2011, 5, 461-478.	1.4	4
59	Direct-acting antiviral agents for the treatment of HCV. <i>Antiviral Therapy</i> , 2012, 17, 1105-1107.	1.0	3
60	Predictors of consent to pharmacogenomics testing in the IDEAL study. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 619-623.	1.5	3
61	How the Human Genome Can Predict Response to Hepatitis C Therapy. <i>Current Hepatitis Reports</i> , 2010, 9, 1-8.	0.3	2
62	Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol. <i>Contemporary Clinical Trials</i> , 2019, 84, 105828.	1.8	2
63	Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019. <i>Epidemiology and Infection</i> , 2022, 150, e7.	2.1	1
64	Biomarkers of Fibrosis and Fibrosis Progression in Chronic Hepatitis C. <i>Current Hepatitis Reports</i> , 2012, 11, 231-242.	0.3	0
65	Reply. <i>Hepatology</i> , 2015, 61, 409-409.	7.3	0
66	In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care. <i>Journal of Viral Hepatitis</i> , 2021, 28, 217-218.	2.0	0